What the FDA labels say about taking them together
Lithium and succinylcholine
Succinylcholine's FDA label of August 18, 2026 names lithium in its drug interactions section; the lithium labels PlainMeds reads (4) do not name succinylcholine. The succinylcholine label: “… quinidine, β-adrenergic blockers, procainamide, lidocaine, trimethaphan, lithium carbonate, magnesium salts, quinine, chloroquine, isoflurane, desflurane, metoclopramide, terbutaline, and drugs that reduce plasma …”
Check it at the source: the lithium FDA label on DailyMed (effective December 23, 2025, Glenmark Pharmaceuticals Inc., USA); the succinylcholine FDA label on DailyMed (effective August 18, 2026, Hospira, Inc.).
What does the lithium label say about succinylcholine?
Lithium's label (effective December 23, 2025) and its 3 other brand-application labels do not name succinylcholine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Lithium Carbonate), Glenmark Pharmaceuticals Inc., USA, effective December 23, 2025 (SPL set 63b3790f-a9b5-47f4-bae1-ddf8b43c13c1), via openFDA; the full label on DailyMed
What does the succinylcholine label say about lithium?
Succinylcholine label, drug interactionsDRUG INTERACTIONS Drugs that May Enhance the Neuromuscular Blocking Action of Succinylcholine: promazine, oxytocin, aprotinin, certain non-penicillin antibiotics, quinidine, β-adrenergic blockers, procainamide, lidocaine, trimethaphan, lithium carbonate, magnesium salts, quinine, chloroquine, isoflurane, desflurane, metoclopramide, terbutaline, and drugs that reduce plasma cholinesterase activity.
Source: FDA drug label (QUELICIN), Hospira, Inc., effective August 18, 2026 (SPL set fb08161e-7711-406d-e7b3-ea4515c07983), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lithium | Succinylcholine | |
|---|---|---|
| Labeled for | Bipolar disorder | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.104 per capsule 300 mg capsule | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once